Mobile Logo

EdR Fund Global Healthcare Thematic equities

Thematic equities
Change in NAV (21/09/2017)
296.12 EUR
Adeline  SALAT-BAROUX–LU1160357155–
Adeline SALAT-BAROUX
Valérie GUELFI–LU1160357155–
Valérie GUELFI
The identity of the managers presented in this document may change during the life of the product.
Risk and reward profile (1)
1234567
Recommended holding period
5 years
296.12 EUR
Change in NAV (21/09/2017)
6
1234567
Risk and reward profile
5 years
Recommended holding period
Change in NAV (21/09/2017)
296.12 EUR
Risk and reward profile
1234567
Recommended holding period
5 years
Adeline SALAT-BAROUX  
Valérie GUELFI  
The identity of the managers presented in this document may change during the life of the product.
Contact

Investment objective

The objective is to grow net assets by investing in companies operating in the healthcare sector, over the recommended investment period.

View more View less

Commentary 31/08/2017

It was Gilead that made the strongest positive contribution this month. The company announced the acquisition of Kite Pharma for $11.9 billion. Kite is a US biotechnology company pioneering new therapies called CAR-T. This technology allows one to ‘reprogramme' the patient's own T-cells and re-inject them in order to boost the immune system and attack tumour cells. Kite should get approval for this product by the year end for treatment of aggressive NHL patients. Studies show an 84% response rate, with a total cure for over 50% of patients. Novartis also announced FDA approval for its CAR-T treatment for refractory patients with acute lymphoblastic leukemia. This announcement validates an extremely innovative mechanism. Galapagos also made progress after the publication of very positive results for its product against idiopathic lung disease (IPF). Teva's comments on ongoing competitive pressures and lower US generic prices have significantly affected the performance of Endo Pharma and Allergan. We have taken our profits on Vertex (up +105% since the beginning of the year) as we feel its valuation now integrates the potential of its product pipeline. Meanwhile, we have been taking advantage of Tesaro and Evolent's weakness to strengthen our positions.

View more View less

Change in NAV

Chart – Base 100 (21/09/2017)
Avertissement
You are about to download the historical data for a portfolio. Please note that past performance is not an indication of future performance and it may vary over time. They may be affected, for example, by changes in exchange rates


Performance K-EUR Cumulative Annualised
Since 01/01/2017

3.76 %

4.77 %

3.76 %

4.77 %

1 Year

2.95 %

3.42 %

2.95 %

3.42 %

3 Year

28.97 %

28.39 %

8.83 %

8.66 %

5 year

105.31 %

105.65 %

15.46 %

15.50 %

Since inception

196.12 %

192.05 %

15.28 %

15.07 %

Since 01/01/2017 1 Year 3 Year 5 year Since inception
Cumulative

Share class (K-EUR)

Benchmark

3.76 %

4.77 %

2.95 %

3.42 %

28.97 %

28.39 %

105.31 %

105.65 %

196.12 %

192.05 %

Annualised

Share class (K-EUR)

Benchmark

2.95 %

3.42 %

8.83 %

8.66 %

15.46 %

15.50 %

15.28 %

15.07 %

*Rolling periods

Annual performance



Statistics

VolatilityTracking ErrorCorrelation coefficientInformation ratioSharpe ratio
Share class K-EURBenchmarkShare class K-EURBenchmarkShare class K-EURBenchmarkShare class K-EURBenchmarkShare class K-EURBenchmark
1 Year*18.88 %14.38 %5.90 %0.97 %0.35 %0.27 %
3 Year *16.53 %14.89 %4.18 %0.97 %0.09 %0.68 %
Max. drawdownAlphaBeta
Share class K-EURBenchmarkShare class K-EURBenchmarkShare class K-EURBenchmark
1 Year*-11.18 %0.03 %1.27 %
3 Year *-24.67 %-0.02 %1.08 %
Max. monthly gain Since inception12.64 %
Max. monthly loss Since inception-17.63 %
Share class K-EUR
Benchmark
1 Year* 3 Year * 1 Year* 3 Year *
Volatility 18.88 % 16.53 % 14.38 % 14.89 %
Tracking Error 5.90 % 4.18 %
Sharpe ratio 0.27 % 0.68 %
Alpha 0.03 % -0.02 %
Correlation coefficient 0.97 % 0.97 %
Information ratio 0.35 % 0.09 %
Max. monthly loss -17.63 %
Max. monthly gain 12.64 %
Max. drawdown -11.18 % -24.67 %
Beta 1.27 % 1.08 %

Fund information

Inception Date (Fund)
30/04/1985
Inception Date (Part)
04/02/2010
Legal form
SICAV
Benchmark
MSCI AC World Health Care (NR)
Currency (fund)
EUR
Currency (share class)
EUR
Distribution Policy
Accumulation
Valuation frequency
Daily
Minimum initial investment
500000.00 EUR
ISIN Code
LU1160357155
AuM (fund)
483 M (EUR)
Regulatory authority
CSSF
EU Regulation
UCITS
Management company
Edmond de Rothschild Asset Management (Luxembourg)
Delegated Management Company
Edmond de Rothschild Asset Management (France)
Incorporation
Luxembourg
Maximum management fee
0,850 %
Current management fee
0.850 %
Subscription and redemption conditions
Daily before 12.30 am C.E.T. on day's net asset value

Fund documentation

Select all

(1) The rating grades the funds on a scale from 1 to 7. This rating system is based on the average fluctuations of the net asset value over the past five years. It corresponds to the variation range of the portfolio upwards and downwards. If the net asset value is less than 5 years old, the rating is determined by other regulatory calculation methods. Historical data such as those used to calculate the rating may not be a reliable indication of the future risk profile. The current category is neither a guarantee nor an objective. Category 1 does not signify a risk-free investment.

Top